Perkins Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-35,632
| Closed | -$132K | – | 129 |
|
|
2017
Q4 | $132K | Sell |
35,632
-15,681
| -31% | -$64.2K | 0.13% | 99 |
|
|
2017
Q3 | $210K | Sell |
51,313
-816
| -2% | -$3.12K | 0.22% | 83 |
|
|
2017
Q2 | $194K | Buy |
52,129
+4,000
| +8% | +$15.9K | 0.22% | 86 |
|
|
2017
Q1 | $199K | Buy |
48,129
+2,887
| +6% | +$12.1K | 0.21% | 93 |
|
|
2016
Q4 | $195K | Sell |
45,242
-641
| -1% | -$4.14K | 0.21% | 89 |
|
|
2016
Q3 | $451K | Sell |
45,883
-5,350
| -10% | -$37.9K | 0.45% | 72 |
|
|
2016
Q2 | $290K | Sell |
51,233
-692
| -1% | -$4.7K | 0.33% | 75 |
|
|
2016
Q1 | $396K | Sell |
51,925
-11,633
| -18% | -$89.6K | 0.5% | 64 |
|
|
2015
Q4 | $847K | Sell |
63,558
-1,550
| -2% | -$26.7K | 0.91% | 35 |
|
|
2015
Q3 | $1.07M | Sell |
65,108
-2,294
| -3% | -$47K | 1.19% | 24 |
|
|
2015
Q2 | $1.51M | Sell |
67,402
-3,865
| -5% | -$61.1K | 1.33% | 20 |
|
|
2015
Q1 | $697K | Buy |
71,267
+89
| +0.1% | +$873 | 0.58% | 63 |
|
|
2014
Q4 | $811K | Sell |
71,178
-6,272
| -8% | -$68.1K | 0.7% | 56 |
|
|
2014
Q3 | $892K | Sell |
77,450
-2,733
| -3% | -$41.7K | 0.75% | 49 |
|
|
2014
Q2 | $1.56M | Sell |
80,183
-1,725
| -2% | -$30.4K | 1.1% | 30 |
|
|
2014
Q1 | $1.47M | Sell |
81,908
-10,567
| -11% | -$174K | 1.03% | 32 |
|
|
2013
Q4 | $977K | Sell |
92,475
-7,458
| -7% | -$83.4K | 0.66% | 60 |
|
|
2013
Q3 | $1.24M | Buy |
99,933
+9,583
| +11% | +$101K | 0.89% | 43 |
|
|
2013
Q2 | $851K | Buy |
+90,350
| New | +$1.16M | 0.68% | 54 |
|
Perkins Capital Management's CASC Position: Q1 2018 in Review
Perkins Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 35,632 shares — an estimated $132K sold.
Perkins Capital Management first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $1.56M in Q2 2014. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Perkins Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Perkins Capital Management sold 35,632 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $132K.
- Perkins Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Perkins Capital Management's Cascadian Therapeutics, Inc. position peaked at $1.56M in Q2 2014.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Perkins Capital Management's 13F filing for Q1 2018, filed 23 Apr 2018.